Prior Authorization Form
|
|
- Carol Cummings
- 6 years ago
- Views:
Transcription
1 5/2/2017 Prior Authorization Form INTOTAL HEALTH PLAN (SPC) Multiple Sclerosis MMT SGM This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS/Caremark at Please contact CVS/Caremark at with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Multiple Sclerosis MMT SGM. Drug Name (specify drug) Quantity Frequency Strength Route of Administration Expected Length of Therapy Patient Information Patient Name: Patient ID: Patient Group.: Patient DOB: Patient Phone: Prescribing Physician Physician Name: Physician Phone: Physician Fax: Physician Address: City, State, Zip: Diagnosis: ICD Code: Comments: Please circle the appropriate answer for each question. 1. What drug is being prescribed? Ampyra Aubagio Avonex Betaseron Copaxone Extavia Gilenya Lemtrada Plegridy Rebif Tecfidera Tysabri
2 Glatopa Zinbryta 2. Betaseron, and Plegridy are the non-preferred products for this patient's health plan. Is the prescriber willing to switch to one of the following drugs? Yes, to Avonex (preferred products) Yes, to Extavia (preferred products) Yes, to Rebif (preferred products) Yes, to Gilenya Yes, to Copaxone Yes, to Aubagio Yes, to Ampyra Yes, to Tecfidera Yes, to Lemtrada Yes, Tysabri Yes, Glatopa, prescriber would like to continue to request Betaseron or Plegridy 3. Is the patient currently receiving the requested product through insurance coverage? te: If the patient is receiving the product through samples or a manufacturer s patient assistance program, please answer. Internal CRU te: Please review the past 120 days of the patient s claim history to confirm at least 28-day supply if Yes. 4. Is the request for Betaseron? 5. Extavia is the Preferred Formulary interferon beta-1b Product for this patient s plan. Can the patient be switched to Extavia? te: Extavia and Betaseron are the exact same products with different labels and brand names, which are made in the same manufacturing facility. 6. Avonex and Rebif are the other Preferred Formulary interferon beta Products for this patient s plan. Can the patient be switched to Avonex or Rebif? Yes, Avonex Yes, Rebif, prescriber would like to continue to request Betaseron 7. Is there a clinical reason that the patient must use Betaseron over Extavia? ACTION REQUIRED: If Yes, attach supporting clinical documents. 8. Avonex, Extavia, and Rebif are the Preferred Formulary interferon beta Products for this patient s plan. Can the patient be switched to one of these preferred products? Yes, Avonex Yes, Extavia Yes, Rebif, prescriber would like to continue to request Plegridy 9. Has the patient tried and had an inadequate response to at least one
3 of the Preferred Formulary interferon beta Products (i.e., Avonex, Extavia, Rebif)? Yes - Indicate the trial duration of Preferred Formulary interferon beta Product 10. Has the patient tried and was intolerant to or had a confirmed adverse event with at least one of the Preferred Formulary interferon beta Products (i.e., Avonex, Extavia, Rebif)? Yes - Indicate intolerance/adverse event(s) to the Preferred Formulary interferon beta Product 11. Does the patient have a contraindication to any of the Preferred Formulary interferon beta Products (i.e., Avonex, Extavia, Rebif) or any of their components? Yes - Indicate contraindication to the Preferred Formulary interferon beta Product(s) 12. Which drug is being prescribed? Betaseron Plegridy 13. Does the patient have a diagnosis of multiple sclerosis? 14. Is this request for continuation of therapy with Ampyra? 15. Is the patient receiving Ampyra through samples or a manufacturer s patient assistance program? 16. Has the patient experienced improvement in walking speed or another objective measure of walking ability since starting Ampyra therapy? 17. Prior to initiation of Ampyra therapy, does/did the patient have sustained walking impairment? 18. What is the diagnosis? 19. What is the diagnosis? (MS) 20. What is the diagnosis? (MS) 21. What is the diagnosis? (MS)
4 22. What is the diagnosis? (MS) 23. What is the diagnosis? 24. What is the diagnosis? ne of the above/ 25. How many courses of Lemtrada treatment has the patient received over his/her lifetime? previous courses (0 dose) One course (5 doses) Two courses or more (8 doses or more) 26. Has the patient had an inadequate response to two or more drugs indicated for multiple sclerosis? 27. What is the diagnosis? 28. What is the diagnosis? (MS) 29. What is the diagnosis? 30. What is the diagnosis? Crohn s disease 31. What is the diagnosis? (MS)
5 32. What is the diagnosis? Relapsing form multiple sclerosis (MS) 33. Has the patient had an inadequate response to two or more drugs indicated for multiple sclerosis? I affirm that the information given on this form is true and accurate as of this date. Prescriber (Or Authorized) Signature and Date
Outline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab)
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0023O Effective Date: June 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0023P Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationThe Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan
The Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan October 7, 2016 Prepared for Institute for Clinical and Economic Review,
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationA Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis
Original Article J Clin Med Res. 2018;10(2):88-105 A Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis Vida Hamidi a, Elisabeth Couto a, Tove Ringerike a, Marianne
More informationThere are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More informationForm 2043 R3.0: Multiple Sclerosis Pre-HSCT data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: EBMT Center Identification Code (CIC): Today's Date: - - Date of HSCT for which this form is being completed: -
More informationFORMULARY MANAGEMENT ABSTRACT
FORMULARY MANAGEMENT Pharmacy Benefit Forecast for a New Interferon Beta-1a for the Treatment of Multiple Sclerosis: Development of a First-Line Decision Tool for Pharmacy-Budget Planning Using Administrative
More informationISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45
ISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45 Introduction Alastair Kent, OBE, Genetic Alliance UK, London, UK Recent HTA decisions Jacco Keja, PhD, IMS Health, Rotterdam, The Netherlands
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationFDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now
FDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now By Angela Maas, Managing Editor April 2017Volume 14Issue 4 In late March, the FDA went on an approval tear, paving the
More informationTysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab
PHARMACOVIGILANCE AND REGISTRY PROGRAMMES Tysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab Eric Van Ganse Pharmacoepidemiology, CHU-Lyon France OUTLINE I. GOOD REGISTRY PRACTICE
More informationwww.ms-coalition.org February 14, 2014 Janet Woodcock, MD Director, Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave Silver Spring, MD 20993 Re: Implications
More informationThe Economics of New Drug Development: Costs, Risks, and Returns
The Economics of New Drug Development: Costs, Risks, and Returns Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism Group Spring Meeting
More informationPATIENT GROUPS & CLINICAL TRIALS CASE STUDY
February 1, 2017 PATIENT GROUPS & CLINICAL TRIALS CASE STUDY Jeffrey W. Sherman, M.D., FACP Past President Inaugural Fellow Chief Medical Officer Executive Vice President Disclaimer The views and opinions
More informationOff-Label Use of FDA-Approved Drugs and Biologicals
Off-Label Use of FDA-Approved Drugs and Biologicals Last Review Date: January 12, 2018 Number: MG.MM.AD.06cC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician
More informationTransitioning to Express Scripts
Transitioning to Express Scripts Welcome to Express Scripts. We re pleased to announce that, beginning January 1, 2017 the Michigan Tech prescription benefit will be managed by Express Scripts. Express
More informationResearch Brief. Findings From HSC NO. 22, APRIL Limited Options to Manage Specialty Drug Spending
Research Brief Findings From HSC NO. 22, APRIL 2012 Limited Options to Manage Specialty Drug Spending BY HA T. TU AND DIVYA R. SAMUEL Spending on specialty drugs typically high-cost biologic medications
More informationBiogen Idec Synergy Creation in the move to the Big League. Activities, Assets and Sales Figures
Biogen Idec Synergy Creation in the move to the Big League Activities, Assets and Sales Figures Biogen Idec is one of the few integrated firms in the biotechnology industry that manages a drug right from
More informationPersonal Check Money Order Credit Card Visa MC Discover Amex LYMPHOCYTE TRANSFORMATION TESTING (LTT) AND/OR METAL ION TESTING SERVICE (ALL FIELDS REQUIRED) Patient Last, First Name, M.I. Mail or e-mail
More informationDaniel Harari 1, *, Irit Orr 2, Ron Rotkopf 2, Sergio E. Baranzini 3 and Gideon Schreiber 1, * Abstract. Introduction ORIGINAL ARTICLE
Human Molecular Genetics, 2015, Vol. 24, No. 11 3192 3205 doi: 10.1093/hmg/ddv071 Advance Access Publication Date: 26 February 2015 Original Article ORIGINAL ARTICLE A robust type I interferon gene signature
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationAs the disease progresses, patients may experience suboptimal response to their current therapy, necessitating a treatment switch.
Comments to ICER s Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Draft Evidence Report We acknowledge the difficult nature of comparing
More informationClinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Clinical Utility of Glatiramer Acetate in the Management
More informationPHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)
PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec) INDICATION IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable
More informationFDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications.
Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of an Individual Patient with an Investigational Drug or a REMS-restricted, Approved Drug Guidelines:
More informationCredit Suisse 7 th Annual European Large Cap Pharmaceutical Conference. November 6, 2007
Credit Suisse 7 th Annual European Large Cap Pharmaceutical Conference November 6, 2007 Safe Harbor Statement This presentation contains forward-looking statements about Elan s financial condition, results
More informationJuly 13, Dear Secretary Price:
July 13, 2017 The Honorable Thomas E. Price, M.D. Secretary U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Secretary Price: At our meeting on May 16,
More informationABSTRACT ORIGINAL RESEARCH. Donald A. Barone. Barry A. Singer. Lubo Merkov. Mark Rametta. Gustavo Suarez
Neurol Ther (2016) 5:155 167 DOI 10.1007/s40120-016-0047-3 ORIGINAL RESEARCH Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT
More informationFAMILY MEDICAL LEAVE ACT (FMLA) OREGON FAMILY LEAVE ACT (OFLA) Human Resources Department P: F:
FAMILY MEDICAL LEAVE ACT (FMLA) OREGON FAMILY LEAVE ACT (OFLA) Human Resources Department P: 541-416-3802 F: 541-323-2262 Medical leaves of absence apply to ANY of the following conditions: Medical leave
More informationUnderstanding Biosimilars and Projecting the Cost Savings to Employers Update
Understanding Biosimilars and Projecting the Cost Savings to Employers Update Prepared by: Milliman, Inc. Frank Kopenski Jr, ASA, MAAA Principal and Consulting Actuary Katie Holcomb, FSA, MAAA Actuary
More informationStreamlining IRB Procedures for Expanded Access
Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs
More informationTITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE
TITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE JULY 23, 2014 Forward-Looking Statements This presentation contains forward-looking statements, including statements about
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More informationMEANINGFUL USE CRITERIA PHYSICIANS
MEANINGFUL USE CRITERIA PHYSICIANS The first list is of the 25 Stage 1 Meaningful Use criteria for eligible providers (EP) and comes from the proposed rule: "Medicare and Medicaid Programs; Electronic
More informationCommunicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017
Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson
More informationZ'S BEES EMPLOYMENT APPLICATION
Z'S BEES EMPLOYMENT APPLICATION I. Personal Information First Name: Last Name: Street Address: City: State: Zip Code: Home Phone: ( ) Cell Phone: ( ) D.O.B Social Security Number And Driver s License Number:
More informationFuture strategies for pricing and market access in oncology
Future strategies for pricing and market access in oncology Discussion document October, 2014 BOSTON CHICAGO DALLAS DENVER LOS ANGELES MENLO PARK MONTREAL NEW YORK SAN FRANCISCO WASHINGTON Agenda We review
More informationSutter Community Connect Downtime Procedure
Purpose Sutter Community Connect Downtime Procedure To ensure that all users and IT staff are aware of the procedures to be used during an outage, and that all users and IT staff are aware of the communication
More informationExpanded Access to Investigational Imaging Drugs
Expanded Access to Investigational Imaging Drugs Phillip B. Davis, MD FDA/CDER/ODEIV/DMIP 6/09/2016 1 Overview Expanded Access (EA) Defined Requirements for all EA authorizations Types of EA Individual
More informationContinued Development of Approved Biological Drugs
Continued Development of Approved Biological Drugs A Quantitative Study of Additional Indications Approved Postlaunch in the United States White Paper December 2007 Maya Said Charles-André Brouwers Peter
More informationNational Learning Consortium
National Learning Consortium The National Learning Consortium (NLC) is a virtual and evolving body of knowledge and tools designed to support healthcare providers and health IT professionals working towards
More informationFIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. Specify countries: Name of person previously tested and relationship:
REQUEST FOR SITE SPECIFIC ANALYSIS [APC / MYH / TP53 / MLH1 / MSH2 / MSH6] Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS
More informationFAMILY MEDICAL LEAVE- YOUR SERIOUS HEALTH CONDITION ACTION ITEMS & INFO
Complete the following action items for a successful continuous or intermittent Family Medical Leave (FML). Action items for intermittent FML follow the continuous FML/Leave of Absence section. Continuous
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationREQUEST FOR RETINOBLASTOMA TESTING
PATIENT INFORMATION REQUEST FOR RETINOBLASTOMA TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS FIRST NAME MI LAST
More informationWHAT S IN A NAME? The Importance of Biosimilar Nonproprietary Names for Healthcare Innovation
POLICY PAPER WHAT S IN A NAME? The Importance of Biosimilar Nonproprietary Names for Healthcare Innovation Sumant Ramachandra, M.D., Ph.D. Senior Vice President and Chief Scientific Officer EXECUTIVE SUMMARY
More informationCarolina Hearts Medical Equipment, LLC
EMPLOYMENT APPLICATION Referred By: Date OFFICE USE ONLY Human Resource Representative Application Received Last Name First Middle Application Reviewed Interview Job Offer Date Start Salary Position Applied
More informationIs FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D
Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite 1100 1050 Connecticut Ave., NW Washington, DC, 20036 D 202-861-1648 LShea@bakerlaw.com FMT Scenarios Intra-Office Bank Product The Issue The
More informationGuidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical
Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of Intermediate-size Patient Populations with an Investigational Drug or a REMS-restricted, Approved
More informationTiming is Everything: The Importance of Early Intervention in Multiple Sclerosis
Timing is Everything: The Importance of Early Intervention in Multiple Sclerosis Challenge Question: Pathophysiology Which of the following is a correct statement about the pathophysiology of MS and/or
More informationUSA Proprietary Name Review Process
USA Proprietary Name Review Process Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Surveillance and Epidemiology (OSE) Division of Medication Errors and Prevention
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationMND Review of Molecular and Genomic Diagnostic Testing Services Questions & Answers
MND Review of Molecular and Genomic Diagnostic Testing Services Questions & Answers 1. What is the Molecular and Genomic Testing Program? Horizon Blue Cross Blue Shield of New Jersey has expanded its collaboration
More informationMEDICAL LEAVE OF ABSENCE REQUEST FORM
MEDICAL LEAVE OF ABSENCE REQUEST FORM Section 1: For completion by the Employee The FMLA permits an employer to require that you submit a timely, complete, and sufficient medical certification to support
More informationThis policy applies to all locations or projects where a Return-to-Work Program may need to be implemented.
Scope and Application This policy applies to all locations or projects where a Return-to-Work Program may need to be implemented. It is our goal to return employees, who have sustained a compensable injury,
More informationIntroduction to the SmPC guideline
Introduction to the SmPC guideline SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group An
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationINSTRUCTIONS: HOW TO COMPLETE THE AVASTIN PATIENT
INSTRUCTIONS: HOW TO COMPLETE THE AVASTIN PATIENT ASSISTANCE PROGRAM ENROLLMENT FORM Phone: (888) 249-4918 Fax: (888) 249-4919 www.avastinaccesssolutions.com Enrollment Requirements Complete the Enrollment
More informationTC 3 Health an Emdeon Company, ICD-10 Frequently Asked Questions. Published Q2 2014
TC 3 Health an Emdeon Company, ICD-10 Frequently Asked Questions Published Q2 2014 Preface This information is provided by TC 3 Health, an Emdeon Company for education and awareness use only. Even though
More informationCopyright 2017 Aegis Sciences Corporation All Rights Reserved
Oral Fluid Collection Healthcare Collection Site Preparation 1. The collection site must have all the supplies needed to complete a specimen collection (e.g. collection kits, ink pens, Custody and Control
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationMEDICAL BILLING ASSOCIATE
MEDICAL BILLING ASSOCIATE Position Description: Responsible for functions of the medical billing and coding office to ensure maximization of cash flow while improving patient, physician, and other customer
More informationYour Prescription Drug [ or 20%] Plan with Refill By Mail
Refill By Mail The Home Delivery Pharmacy sends drugs you take on a regular basis right to your door. And you get a larger supply of medicine for less money. 1 Your Prescription Drug [15-40-75 or 20%]
More informationFIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. P70.4 Neonatal hypoglycemia Q79.59 Omphalocele P08.1 Large for gestational age
REQUEST FOR BECKWITH-WIEDEMANN SYNDROME (BWS) TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION*
More informationGlossary of terms used in Pharmacovigilance
Glossary of terms used in Pharmacovigilance WHO - World Health Organization CIOMS - Council for International Organizations of Medical Sciences ICH - International Conference on Harmonization PSUR - Periodic
More informationPhysician Office Billing & Payment Guide
Physician Office Billing & Payment Guide Dermal Regeneration Matrix Dermal Repair Scaffold Ag Antimicrobial Dermal Repair Scaffold Physician Office Billing & Payment Guide Billing and Medicare Payment
More informationTexas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationGeriMedProfiles. Consultant Pharmacist Software
GeriMedProfiles Consultant Pharmacist Software Features GerimedProfiles TM is a comprehensive medical database for clinical pharmacists Utilizes Microsoft Access as the core database allowing the end-user
More informationClinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationUsing Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing
Using Your Prescription Drug Program Answers to important questions about retail pharmacy and mail order purchasing Welcome! We know you re going to enjoy the many advantages of your prescription drug
More informationThe transition to OptumRx is designed to help us better serve your employees and help improve their overall experience:
September 27, 2013 RE: Pharmacy Benefit Transition Plan for Oxford Clients Dear Valued Oxford Client, We are pleased to confirm that, effective Oct. 1, 2013, your pharmacy benefit services are being administered
More informationWelcome to B.C. PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process.
Welcome to B.C. PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. This caregiver questionnaire is for [enter name of SEB under review] which is being
More informationFAMILY AND MEDICAL LEAVE ACT OF 1993
Division of Administrative Services HUMAN RESOURCES FAMILY AND MEDICAL LEAVE ACT OF 1993 Employee Packet Division of Administrative Services HUMAN RESOURCES North End Center 300 Turner St. NW Suite 2300
More informationOLD WEST FEDERAL CREDIT UNION An Equal Opportunity Employer 162 West Front St Prairie City, Or (541)
650 West Main St John Day, Or 97845 (541) 575-0264 3 Depot Streeet La Grande, OR 97850 (541) 963-3053 OLD WEST FEDERAL CREDIT UNION An Equal Opportunity Employer 162 West Front St Prairie City, Or 97869
More informationPharmacy. Medication. Checks
Pharmacy Medication Checks Module 2 Table of Contents Section A... 1 A.1 Clinical Medication Order Check... 1 A.2 Final Product and Computer Order Entry Check... 1 Section B... 2 B.1 Documentation of Pharmacy
More informationHi, I'm Derek Baker, the Executive Editor of the ibm.com home. page, and I'm here today to talk with Dan Pelino, who Is IBM's General Manager for
Hi, I'm Derek Baker, the Executive Editor of the ibm.com home page, and I'm here today to talk with Dan Pelino, who Is IBM's General Manager for the Healthcare and Life Sciences Industries; and also, with
More informationPrescription Writing Version 4.81
Prescription Writing Version 4.81 Contents Introduction... 1 Field Definitions... 1 Patient Prescription Entry Window... 1 Void Patient Prescription Window... 5 Drug Dose Frequencies Window... 6 Pharmacies
More informationCoding Systems Understanding NDC and HCPCS
Coding Systems Understanding NDC and HCPCS National Drug Code The National Drug Code (NDC) serves as a universal product identifier for prescription medications approved for human consumption. According
More informationPHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14
PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14 Submitted resources from physician organization representatives were mapped
More informationNEUTRALIZING ANTIBODY TESTS FOR INTERFERON
NEUTRALIZING ANTIBODY TESTS FOR INTERFERON Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationNEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY
NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY MEMORANDUM IN SUPPORT OF AN AMENDMENT TO NEW YORK S PHARMACY LAW
More informationThe Drug Approval Process in Canada
The Drug Approval Process in Canada Ryan Clarke Saturday, April 26, 2014 Overview Process Drug approvals Pricing Common Drug Review Listings (QC) Process Public drug formularies are impacted by federal,
More informationTEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY
1. Patient Information Patient Name TEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY HudsonAlpha Clinical Services Lab, LLC HUDSONALPHA CLINICAL SERVICES LABORATORY
More informationOHM MODULES. Appointment Scheduler. Billing Manager. For more information call or visit ULehssustainability.com/ohm
OHM MODULES Occupational Health Manager (OHM) is a multi-module software solution that gives you all the detailed tracking and reporting tools you need to streamline information management, maximize consistency
More informationPayer Specification Sheet For Prime Therapeutics BCBS of New Mexico Blue Cross Community Centennial (Medicaid)
Specification Sheet For Prime Therapeutics BCBS of New exico Blue Cross Community Centennial (edicaid) General information Prime Therapeutics LLC January 24, 2018 Plan Name BIN PCN BCBS of New exico Blue
More informationPharmacovigilance & Signal Detection
Pharmacovigilance & Signal Detection 30 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Pre-conference educational session Thursday, October 23, 2014; 2:00-6:00pm Semi-automated,
More informationH-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS
H-20 Page 1 of 5 Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS PURPOSE: To describe the requirements for McLeod Health IRB review of Humanitarian Use Devices (HUD).
More informationSpecialty Drug Spending
Specialty Drug Spending The IMS Institute for Healthcare Informatics reported that spending on specialty pharmaceuticals almost doubled from 2010 to 2015, and spending on this subset of drugs was responsible
More informationIllumina Clinical Services Laboratory
Illumina Clinical Services Laboratory CLIA Certificate No.: 05D1092911 Illumina Clinical Services Laboratory TruGenome Technical Sequence Data Test Requisition Form The Illumina Clinical Services Laboratory
More informationDirucotide (MBP8298) for the treatment of multiple sclerosis
DRUG EVALUATION Dirucotide (MBP8298) for the treatment of multiple sclerosis Clyde Markowitz University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104, USA Tel.: +1
More informationREGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts
REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you
More information